The U.S. Food and Drug Administration issued a fresh wave of enforcement letters aimed at telehealth and compounding pharmacies marketing unapproved compounded versions of GLP‑1 diabetes and weight‑loss drugs. The agency sent 30 warning letters citing false or misleading claims that compounded products were equivalent to approved branded medicines and warned of legal remedies if firms fail to respond. The action continues an ongoing regulatory campaign to curb misleading marketing and patient safety risks tied to non‑FDA‑approved compounded copies of semaglutide and tirzepatide. The FDA emphasized that compounded products are not FDA‑approved and cannot be marketed as such. Industry trade groups and telehealth providers are now navigating heightened scrutiny as regulators seek to protect branded product supply chains and safety standards. On the same front, regulators and companies are debating how enforcement will balance patient access, compounding’s legitimate niche uses, and aggressive direct‑to‑consumer telehealth marketing. The uptick in enforcement is likely to trigger compliance reviews across telemedicine platforms and compounders offering GLP‑1 alternatives.